Trials / Unknown
UnknownNCT03442205
Treatment of Common Bile Duct Stones
Randomized Clinical Trial Investigating the Best Method of Treatment of Common Bile Duct Stones
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
ABSTRACT Introduction: Common bile duct (CBD) stone is a common clinical situation, especially in Asia area. Laparotomy and laparoscopic surgical procedure are often used for treatment. This study compares outcomes of different surgical procedures treating for the disease. Methods/design: This is a prospective, randomized, controlled multicenter trial with three treatment arms. One group underwent laparoscopic cholecystectomy (LC) + laparoscopic CBD exploration (LCBDE) + intraoperative endoscopic nasobiliary drainage ENBD + primary closure of CBD. The other underwent preoperative endoscopic retrograde cholangiopancreatography (ERCP) and subsequent LC and the third arm underwent laparoscopic cholecystectomy (LC) + laparoscopic CBD exploration (LCBDE) + primary closure of CBD. The duration of the entire trial is two years including prearrangement, follow-up and analyses. Discussion: Despite the fact plenty evidences provided by meta-analyses suggests that these approaches would appear comparable. It is hopeful to fully address which would be the better approach with this RCT design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | LC + LCBDE + ENBD + primary closure of CBD | LC + LCBDE + ENBD + primary closure of CBD |
| PROCEDURE | ERCP technique + LC | ERCP technique + LC |
| PROCEDURE | LC + LCBDE + primary closure of CBD | LC + LCBDE + primary closure of CBD |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2020-03-01
- Completion
- 2021-03-01
- First posted
- 2018-02-22
- Last updated
- 2018-03-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03442205. Inclusion in this directory is not an endorsement.